Lenalidomide for Second-line Treatment of Advanced Hepatocellular Cancer: a Brown University Oncology Group Phase II Study.

Howard Safran; Kevin P. Charpentier; Andreas Kaubisch; Kalyan Mantripragada; Gregory Dubel; Kimberly Perez; Katherine Faricy-Anderson; Thomas Miner; Yoko Eng; Joel Victor; Angela Plette; Joseph Espat; Pamela Bakalarski; Patti Wingate; David Berz; Denise Luppe; Diane Martel; Kayla Rosati; Santiago Aparo

doi:10.1097/COC.0b013e3182868c66

Lenalidomide for Second-line Treatment of Advanced Hepatocellular Cancer: a Brown University Oncology Group Phase II Study.

Howard Safran, Kevin P. Charpentier, Andreas Kaubisch, Kalyan Mantripragada, Gregory Dubel, Kimberly Perez, Katherine Faricy-Anderson, Thomas Miner, Yoko Eng, Joel Victor, Angela Plette, Joseph Espat, Pamela Bakalarski, Patti Wingate, David Berz, Denise Luppe, Diane Martel, Kayla Rosati, Santiago Aparo

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	American Journal of Clinical Oncology
Volume	38
DOIs	https://doi.org/10.1097/COC.0b013e3182868c66
State	Published - Jan 2 2015

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1097/COC.0b013e3182868c66License: Unspecified

Cite this

Safran, H., Charpentier, K. P., Kaubisch, A., Mantripragada, K., Dubel, G., Perez, K., Faricy-Anderson, K., Miner, T., Eng, Y., Victor, J., Plette, A., Espat, J., Bakalarski, P., Wingate, P., Berz, D., Luppe, D., Martel, D., Rosati, K., & Aparo, S. (2015). Lenalidomide for Second-line Treatment of Advanced Hepatocellular Cancer: a Brown University Oncology Group Phase II Study. American Journal of Clinical Oncology, 38. https://doi.org/10.1097/COC.0b013e3182868c66

Safran, H, Charpentier, KP, Kaubisch, A, Mantripragada, K, Dubel, G, Perez, K, Faricy-Anderson, K, Miner, T, Eng, Y, Victor, J, Plette, A, Espat, J, Bakalarski, P, Wingate, P, Berz, D, Luppe, D, Martel, D, Rosati, K & Aparo, S 2015, 'Lenalidomide for Second-line Treatment of Advanced Hepatocellular Cancer: a Brown University Oncology Group Phase II Study.', American Journal of Clinical Oncology, vol. 38. https://doi.org/10.1097/COC.0b013e3182868c66

@article{5165f66a82b54490884cbcadd5ee8e30,

title = "Lenalidomide for Second-line Treatment of Advanced Hepatocellular Cancer: a Brown University Oncology Group Phase II Study.",

author = "Howard Safran and Charpentier, {Kevin P.} and Andreas Kaubisch and Kalyan Mantripragada and Gregory Dubel and Kimberly Perez and Katherine Faricy-Anderson and Thomas Miner and Yoko Eng and Joel Victor and Angela Plette and Joseph Espat and Pamela Bakalarski and Patti Wingate and David Berz and Denise Luppe and Diane Martel and Kayla Rosati and Santiago Aparo",

note = "Purpose: To assess the activity and toxicity of lenalidomide for patients with advanced hepatocellular cancer (HCC) previously treated with sorafenib. Materials and methods: Patients with advanced HCC who progressed on or were intolerant to sorafenib were eligible. Patients received lenalidomide 25 mg orally for 1 to 21 days in a 28-day cycle until disease progression or unacceptable toxicities.",

year = "2015",

month = jan,

day = "2",

doi = "10.1097/COC.0b013e3182868c66",

language = "American English",

volume = "38",

journal = "American Journal of Clinical Oncology",

}

TY - JOUR

T1 - Lenalidomide for Second-line Treatment of Advanced Hepatocellular Cancer: a Brown University Oncology Group Phase II Study.

AU - Safran, Howard

AU - Charpentier, Kevin P.

AU - Kaubisch, Andreas

AU - Mantripragada, Kalyan

AU - Dubel, Gregory

AU - Perez, Kimberly

AU - Faricy-Anderson, Katherine

AU - Miner, Thomas

AU - Eng, Yoko

AU - Victor, Joel

AU - Plette, Angela

AU - Espat, Joseph

AU - Bakalarski, Pamela

AU - Wingate, Patti

AU - Berz, David

AU - Luppe, Denise

AU - Martel, Diane

AU - Rosati, Kayla

AU - Aparo, Santiago

N1 - Purpose: To assess the activity and toxicity of lenalidomide for patients with advanced hepatocellular cancer (HCC) previously treated with sorafenib. Materials and methods: Patients with advanced HCC who progressed on or were intolerant to sorafenib were eligible. Patients received lenalidomide 25 mg orally for 1 to 21 days in a 28-day cycle until disease progression or unacceptable toxicities.

PY - 2015/1/2

Y1 - 2015/1/2

UR - https://pubmed.ncbi.nlm.nih.gov/23648434/

U2 - 10.1097/COC.0b013e3182868c66

DO - 10.1097/COC.0b013e3182868c66

M3 - Article

VL - 38

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

ER -

Lenalidomide for Second-line Treatment of Advanced Hepatocellular Cancer: a Brown University Oncology Group Phase II Study.

Disciplines

Access to Document

Other files and links

Cite this